Introduction
Genetic and epigenetic changes play an extremely large role in the etiology of cancer. 1 Cancer is usually a disorder of aged individuals and uncommon in children. If cancer occurs in children this suggests an increased susceptibility to develop cancer. 2 Consequently, cancer in children will be frequently caused by a genetic change (mutation) and thus can be inherited. There are numerous examples of cancers occurring within families. 3 Mutations in the same gene can occur both in inherited tumors (germline mutations) and in sporadic tumors (somatic mutations). 4 Well-known examples of this are sporadic basal cell carcinoma and Gorlin syndrome (GS), or sporadic meningioma and neurofibromatosis type 2 (NF2).
In patients with inherited mutations of genes that can cause cancer, the inherited mutation itself is not sufficient to cause cancer: cells from such patients need to acquire one or more further mutations (Knudson two-hit theory). 5, 6 Not everyone will acquire such a second mutation, so not everyone who inherits a mutation in a cancer gene will indeed develop cancer. In hereditary tumor disorders, patients can develop multiple primary tumors as the second hit can occur independently at different loci. Furthermore, as children with a hereditary predisposition already have the first hit at conception, they are usually younger developing a tumor compared with their sporadic counterparts caused by acquired somatic mutations. 7 Keywords ► infant ► child ► brain tumor ► gene ► genetic ► malformation ► syndrome ► surveillance Abstract (Brain) tumors are usually a disorder of aged individuals. If a brain tumor occurs in a child, there is a possible genetic susceptibility for this. Such genetic susceptibilities often show other signs and symptoms. Therefore, every child with a brain tumor should be carefully evaluated for the presence of a "tumor predisposition syndrome." Here, we provide an overview of the various central nervous system tumors that occur in children with syndromes and of the various syndromes that occur in children with brain tumor. Our aim is to facilitate recognition of syndromes in children with a brain tumor and early diagnosis of brain tumors in children with syndromes. Diagnosing tumor predisposition syndromes in children may have important consequences for prognosis, treatment, and screening for subsequent malignancies and nontumor manifestations. We discuss pitfalls in clinical and molecular diagnoses, and the consequences of diagnosing a hereditary disorder for family members. Our improved knowledge of cancer etiology is increasingly translated into management strategies in syndromes in general and will likely lead in the near future to personalized therapeutic approaches for tumor predisposition syndromes.
Genes and their corresponding proteins have (almost) invariably a dual function, one prenatally and one postnatally: A gene that steers the formation of an organ or body part (developmental gene) during embryogenesis, frequently becomes a gene that is involved in growth regulation after birth. 4 Subsequently, we may expect that a mutated developmental gene causes an unusual phenotype or syndrome prenatally and may go along with an increased risk for the same individual to develop cancer postnatally. Indeed, children with congenital anomalies and syndromes have a higher risk to develop cancer, 8 including tumors of the central nervous system (CNS). 9, 10 In addition, children with cancer have more morphological abnormalities, 11 malformations, 12 and more syndromes as well. 13 The recognition of syndromes in children is often problematic as it needs proper examination by a clinical geneticist or a pediatrician skilled in clinical morphology and obtaining a detailed family history to detect this (►Fig. 1). 14 Like other types of cancer, tumors of the CNS usually occur in adults. Only 7% of CNS tumors occur in children. 15 CNS tumors are relatively frequent compared with other types of cancer in children, and comprise approximately 25% of all childhood tumors. 16 Some CNS tumors in children (embryonal CNS tumors as medulloblastoma and ependymoma, and also pilocytic astrocytoma) are linked to factors contributing to brain growth early in (postnatal) life, 17 as these tumors occur less frequent with increasing age. 15 In contrast, during adolescence, the incidence of intracranial germ cell tumors peaks suggesting that puberty itself either initiates or drives their growth. 17 The increased risk for a child with malformations to develop a tumor 8 is reflected in the increased risk for children with CNS malformations to develop CNS tumors. 10 For example, closing defects of the neural tube (including occult spinal dysraphism) are known to have a higher co-occurrence of both intracranial and intraspinal lipoma and teratoma. [18] [19] [20] Furthermore, the same pathway seems to be aberrantly activated in different disorders. For example, the SHH-PTCH-GLI pathway is involved in holoprosencephaly, Smith-Lemli-Opitz syndrome, pediatric medulloblastomas and GS (►Table 1). 21 Recently, an overview of somatic mosaic mutations in neurodevelopmental and overgrowth syndromes was provided, and some of these genes (or pathways they act in) are also involved in tumor predisposition syndromes. 22 To our knowledge, no overall analysis has been published on the frequency of CNS tumors in children with a genetic syndrome or the occurrence of syndromes in children with a CNS tumor. Here, we provide a review of the various CNS tumors that occur in children with syndromes and of the syndromes that occur in children with brain tumors. With this, we aim to facilitate recognition of syndromes in children with a brain tumor and early diagnosis of brain tumors in children with syndromes. First, we address from a tumor perspective, which syndromes may be associated with the specific CNS tumor type (►Table 1). Next, we concentrate on well-characterized hereditary syndromes that result from germline mutations in highpenetrance genes and predispose to CNS tumor development (►Table 2). We do not provide data on brain tumors caused by somatic mutations. Because of limited space we have not aimed to be exhaustive for each syndrome, but have put emphasis on the most frequent (morphologic) manifestations and most prevalent syndromes. We acknowledge that most pediatricians and neurologists may not be familiar with the terminology used in clinical genetics and dysmorphology and have provided short descriptions of the main terms used in ►Table 3. This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. 24 To decrease the number of citations, we do not refer to original references but to the above main sources. All syndromes resulting from our searches, in which at least once a CNS tumor was reported, have been included in this overview. In infrequent entities, it may remain uncertain whether the co-occurrence of a tumor is explainable by chance or has a true causal relation. Therefore, the present overview (►Table 1) may contain overestimations of associations between CNS tumors and syndromes. We have accepted this as in our opinion it is preferable to report all known possible associations instead of exclusion of true but presently uncertain associations.
In ►Table 1, only major (morphologic) manifestations are reported. Therefore, other manifestations that may be seen in children do not exclude the presence of either one of the mentioned syndromes.
Results
General ►Table 1 contains all major brain tumor types occurring in children and the various syndromes that have been reported to be associated with these tumors. ►Table 2 contains a short overview of all major tumor predisposition syndromes. The most frequent entities with a high chance to develop a brain tumor are summarized in ►Table 2. We provide short descriptions restricted to major presentations and co-occurring brain tumor of each of the entities below.
Neurofibromatosis Type 1
The first clinical suspicion of NF1 (Recklinghausen disease) should be raised when in an infant or child multiple café-aulait spots are noticed. NF1 may not be obvious immediately: 
Genetic vocabulary
• Names of genes: These are derived from HGNC (http://www.genenames.org/) and are listed in capitals and italics to indicate their human origin (gene names in animal models are in small letters and italics). • Names of proteins: These may be similar to the gene which encodes for it, but can also be completely different (examples: the gene NF1 encodes for the protein Neurofibromin; the gene NF2 encodes for the protein Merlin). A protein name of human origin starts with a capital (protein names in animal models are without a capital). • Names of syndromes: These may be related to the name of the gene causing it, but can also be completely different (examples: mutations in NF1 cause NF1; mutations in TP53 cause LFS). • Syndrome: A pattern of anomalies, at least one of which is morphologic, known or thought to be causally (etiologically) related. 91 • Tumor predisposition syndrome: A syndrome in which a germline mutation leads to increased susceptibility (typically > 5%) to develop a syndrome-related tumor. • Genotype: The primary DNA sequence, either overall or at a specific locus, of an individual or of the organ(s), tissue(s), or cell(s) of that individual. The genotype includes both the nuclear and mitochondrial DNA sequence, and is the counterpart of the phenotype. 91 • Phenotype: All morphologic and functional attributes of an individual, or of the organs, tissues, or cells of that individual. 91 • Penetrance: The proportion of genotypes that actually show the expected phenotype. Penetrance is frequently an agedependent phenomenon, so individuals with a particular genotype can gradually develop (part of) the expected phenotype over time (example: in NF1 children are usually born with some café-au-lait spots but may develop more in time, and later during life also freckling, Lisch nodules, and neurofibromas may become evident). • Expressivity: The severity of the phenotype (examples: NF1 can show in a child all manifestations, but can be detected in its parent only by careful directed searches for café-au-lait spots and freckling, which can be present only in a very limited way). • Germline mutation: A mutation that occurs in all cells of the body including the germ cells. Therefore, the mutation is hereditary and can be passed on to offspring. • Somatic mutation: A mutation that occurs in any cell of the body except germ cells (example: a cell that acquires somatic mutations during life and undergoes malignant transformation to form a sporadic tumor). Therefore, the mutation is not hereditary and cannot be passed on to offspring. • De novo mutation: A germline mutation that has arisen in an individual and is not inherited from either parent. The chance for the parents to have another affected child is not increased, except in case of gonadal mosaicism. The affected child can transmit the abnormal gene to its own offspring (example: NF2 mutations arise de novo in 50%, therefore only half of the NF2 patients can have a positive family history for NF2). • Mosaicism: A mutated gene is not present in all tissues of an individual, but only in (part of) the its cells (example: 30% of NF2 patients mutations are not detected in the blood as a result of somatic mosaicism, but only in an affected body part). • Gonadal mosaicism: A mutated gene is not present in all tissues of an individual, but only in (part of) the egg cells or sperm cells. The individual himself/herself does not show the phenotype and the mutated gene is not found in its blood, but can be passed on to offspring who will then have the mutated gene in all body cells and show the phenotype. If gonadal mosaicism is present, this can be passed on to more than a single child, so there is a recurrence risk for sibs of the affected child. Typically this recurrence risk is around 1% but in some entities it can be much higher (example: 6% in TSC). • Microdeletion syndrome: Genetic disorder caused by a deletion of a segment of chromosome (example: both NF1 and NF2 may be caused a deletion of a segment of a chromosome including the NF1 or NF2 gene). • Next-generation sequencing: A high-throughput method of sequencing, allowing sequencing the complete genome or large regions of the genome in a short period of time for acceptable costs. abnormalities occur more often in NF1 patients. In NF1 patients, exposure to diagnostic and therapeutic radiation should be minimized to avoid the risk of radiation-induced malignancies. With an extreme clinical variability even within families, the genotype-phenotype correlation is complex in NF1. A few correlations have been identified thus far. A more severe phenotype occurs in NF1 patients who have a microdeletion (5-10% of patients) due to a loss of approximately 1.5 Mb at 17q including the NF1 gene, whereas a milder phenotype is observed in NF1 patients with a common 3bp in frame deletion in exon 17. Other genotype-phenotype correlations have been described for spinal neurofibromatosis, optic pathway gliomas, and Watson syndrome. The life expectancy of individuals with NF1 is about 8 years lower compared with the general population. 30 A NF1-Noonan syndrome phenotype occurs in approximately 12% of individuals with NF1 and is caused by NF1 mutations. Affected individuals have a phenotype that combines NF1 and Noonan syndrome including ocular hypertelorism, down-slanting palpebral fissures, low-set ears, webbed neck, and pulmonic stenosis.
Neurofibromatosis Type 2
The hallmark of NF2 is (bilateral) vestibular schwannoma, which typically present with hearing disabilities, tinnitus, and balance dysfunction in patients by their third decades. NF2 is generally considered an adult-onset disease, however, in childhood skin features (schwannomas and café-au-lait spots) and ocular findings (cataract, strabismus, and amblyopia) may be evident but remain often unrecognized. 31, 32 Dermatological and ophthalmological manifestations can sometimes resemble NF1. 33, 34 Furthermore in children, palsy due to mononeuropathy is an increasingly recognized finding. As most patients (50-75%) develop (often multiple) meningioma, any childhood meningioma should be considered as a possible early sign of NF2. Two-third of NF2 patients develop spinal tumors, both with extramedullary (schwannoma and less frequent meningioma) and intramedullary (ependymoma and rarely pilocytic or diffuse astrocytoma) localization. Penetrance is almost 100%. Truncating mutations have been associated with earlier onset and more NF2associated tumors. 34 Furthermore, when NF2 presents in children, the phenotype is usually more severe because of symptoms of meningioma. 35 With earlier diagnosis and novel therapeutic strategies such as cochlear and brain stem implants, life expectancy and quality of life has improved considerably. Still, many NF2 patients have a limited survival (15 years after initial diagnosis).
Rhabdoid Tumor Predisposition Syndrome and Schwannomatosis
In early childhood, RTPS is characterized by an increased risk for developing malignant rhabdoid tumors (MRTs). MRTs may be localized in the kidney, extra renal but intra-abdominally or in the CNS. CNS-localized MRTs are called atypical teratoid/ rhabdoid tumors (AT/RTs), which are highly malignant and have a limited survival, despite aggressive multimodality therapy (surgery, irradiation, and chemotherapy). AT/RTs generally present before the age of 3 years, an age at which radiation therapy is relatively contraindicated because of an increased vulnerability to long-term neurocognitive deficits. 36 Penetrance is highly variable. 13 In children with an AT/RT in which no SMARCB1 mutation is found, germline mutations in SMARCA4 may be considered. 37 In families with RTPS, choroid plexus carcinoma (CPC), infratentorial medulloblastoma and supratentorial primitive neuroectodermal tumors (PNETs) have been reported as well. 38 However, it is possible that these cases because of similar histologies have been misdiagnosed and may in fact represent AT/RTs with a prominent epithelial component, as was afterward shown for the medulloblastoma reported in that study. 39 SMARCB1 germline mutations are also found in 40 to 50% of families with schwannomatosis (previously referred to as NF3). 40, 41 The main distinction with NF2 is that schwannoma in RTPS are generally not localized at the nervus vestibularis. 41, 42 At adult age, sometimes meningioma, preferentially located at the falx, may be seen. 43 At this moment, only three families have been described with a combined phenotype of both RTPS and schwannoma. This suggests that the combined phenotype is rare. However, if RTPS patients survive, they may suffer at adult age from schwannoma. 41 A genotypephenotype correlation likely explains why not in all schwannomatosis families the risk for MRT is increased. 13 Germline mutations in SMARCB1 and related genes have been found to cause Coffin-Siris syndrome, 44 but until now no individual with a molecularly confirmed syndrome diagnosis has developed an AT/RT malignancy. 45 von Hippel-Lindau Disease von Hippel-Lindau Disease (VHL) disease is characterized by hemangioblastomas of the CNS and retina, pheochromocytoma, renal cysts and clear cell carcinoma, and other visceral cysts. Penetrance of VHL is close to 100%. At the age of 65 years, most patients have VHL-related manifestations. However, the manifestations and severity are highly variable both within and between families. Although hemangioblastomas typically occur in young adults, the occurrence of a hemangioblastoma in a child or adolescent should point to VHL as multiple hemangioblastomas are likely to develop. 46 Most VHL patients have multiple hemangioblastomas, which are localized in the brain stem, spinal cord, and nerve roots, compared with sporadic hemangioblastomas which are generally localized in the cerebellum. Hemangioblastomas are frequently accompanied by cysts which can cause symptoms because of their rapid growth. To avoid cysts to recur, complete surgical removal of the hemangioblastomas is essential, and gamma knife treatment is not sufficient. On the basis of genotype, four different VHL phenotypes have been suggested to predict the likelihood to develop pheochromocytoma or renal cell carcinoma. Median life expectancy is significantly lower in VHL patients, 30 as approximately 70% of individuals with VHL develop renal cell carcinoma which is the major cause of death. eyes (50%), and renal (60%) and skin abnormalities (nearly 100%). At birth, hypomelanotic macules, sometimes only visible with a Wood lamp, may be present. Before the age of 15 years most children with TSC have manifestations. 47 Epilepsy (up to 80%), intellectual disability (40%), and behavioral problems due to cortical tubers, subependymal hamartomatous nodules and intracranial calcifications are frequently seen. Penetrance is thought to be 100%. TSC exhibits extreme variability in clinical findings both among and within families. The severe end of the spectrum is represented by the classic triad consists of seizures, intellectual disability, and angiofibroma. Patients with TSC1 mutations are usually less severely affected than patients with TSC2 mutations, and females tend to have milder disease than males. In 10 to 15% of individuals with TSC, usually within the first two decades of life, a subependymal giant cell astrocytoma (SEGA) may be detected. SEGA is a benign, slowly growing tumor, typically arising unilateral or bilateral in the wall of the lateral ventricles, and virtually pathognomonic of TSC. 48 Treatment of enlarging SEGAs may consist of mammalian target of rapamycin (mTOR) inhibitors; if size causes life-threatening neurologic symptoms neurosurgery is unambiguously indicated.
Li-Fraumeni Syndrome
LFS is characterized by multiple primary tumors in children and young adults. The predominant tumors are brain tumors, bone and soft tissue sarcomas, breast, and adrenocortical tumors. Half of LFS-associated malignancies are estimated to occur before the age of 30 years. Individuals with LFS are at increased risk of developing various types of generally highly malignant brain tumors (astrocytomas, glioblastomas, medulloblastomas, CPC). The median age of onset for brain tumors is 16 years, suggesting that more than half of LFS-associated brain tumors occur in children younger than 18 years. The risk for brain tumors has been reported to be increased if the TP53 mutation lies in the DNA-binding loop that contacts the minor groove of DNA. Children with a CPC, who typically present at young age ( 3 years), are at high risk to harbor a TP53 germline mutation, even in the absence of a positive family history, due to de novo mutations. 49, 50 In a recent report, TP53 germline mutations were also found children with medulloblastoma of the sonic hedgehog subtype (SHH-MB) with chromothripsis. 51 In SHH-MB, typically presenting between 5 and 18 years of age, 12% of TP53 germline mutations were identified. 52 Overall, LFS is known to give a high lifetime risk for a range of tumors: 93% in woman and 75% in men, with an estimated 30 to 40% risk for cancer in childhood and adolescence. 53 In LFS affected family members, the risk to develop a second or third malignancy was estimated to be 15 and 4%, respectively. For 30 childhood cancer survivors, these risks were considerably higher (57 and 38%). Various genotypephenotype correlations have been reported. Because of the high risk to develop (multiple) malignant tumors, overall survival is limited. Preliminary studies have shown positive aspects of early diagnosis and surveillance in LFS patients for overall survival. 53 In LFS patients, exposure to diagnostic and therapeutic radiation should be minimized to avoid the risk of radiation-induced malignancies.
Gorlin Syndrome
Individuals with GS (nevoid basal cell carcinoma syndrome) have congenital abnormalities such as bifid or fused ribs or wedge-shaped vertebra (> 50%), often macrocephaly (> 50% above > 97th percentile), sometimes cleft lip and/or palate (5%) and polydactyly (5%). Jaw keratocysts develop around their teens; sporadic reports of ameloblastoma arising in these are known. Generally, basal cell carcinoma of the skin are seen starting in adolescence or early adulthood, unless prior exposure to radiotherapy. Palmar and plantar pits can be seen in most patients (►Fig. 2A). Approximately 5% of GS patients present during their first years of life with a medulloblastoma. These medulloblastomas have desmoplastic histology with an expression pattern indicating activation of the sonic hedgehog signaling pathway and have a more favorable prognosis compared with their sporadic counterparts. Treatment of medulloblastoma exists of surgical resection, (intrathecal) chemotherapy and irradiation in indicated cases (e.g., metastatic cases or residual disease after surgery). 54 It has been suggested that young children presenting with medulloblastoma of nodular or desmoplastic histology need to be assessed for GS. 54, 55 In PTCH1-negative children younger than the age of 3 years with a desmoplastic/nodular medulloblastoma, with and without other manifestations fitting GS, germline mutations in suppressor of fused homolog (SUFU) have been identified. Nontumor CNS manifestations include calcification of the falx cerebri or tentorium cerebellum, present in 90% of individuals by the age of 20 years. Meningioma are also reported to occur with an increased frequency in GS patients, furthermore, incidental cases of astrocytomas, oligodendroglioma, and craniopharyngioma have been reported. Penetrance is probably 100%, and expression is highly variable also within a single family. Except for an increased chance for intellectual disability in individuals with a microdeletion that include PTCH1, no genotype-phenotype correlations have been recognized. Patients with GS generally have a good prognostic outcome with (near) normal life expectancy. 30 
Cowden Syndrome
Cowden syndrome (CS) is one of the clinical manifestations of the phosphatase and tensin homolog (PTEN) hamartoma tumor syndromes and is characterized by multiple hamartomas and a high risk for benign and malignant tumors of predominantly the thyroid, breast, and endometrium. Patients with CS usually present by their 20s when mucocutaneous manifestations (►Fig. 2B) have been developed. Dysplastic gangliocytoma of cerebellum, also known as Lhermitte-Duclos disease (LDD), is the pathognomonic CNS manifestation of CS. LDD is a rare benign hamartomatous overgrowth composed of dysplastic ganglion cells in the cerebellum and usually arises at adult age, but affected children do occur. Sporadically occurring meningioma, medulloblastoma, gangliocytoma, and glioblastoma have been reported at adult age in patients with CS. Additional cerebral manifestations of CS include macrocephaly in 20 to 70% of cases (often skull circumferences are three standard deviation or more above the mean), hydrocephalus, intellectual disability, autism, and seizures. In children diagnosed with CS, neurodevelopmental evaluation is generally useful. An age-dependent penetrance has been observed, becoming complete in the late fourth decade. Because of the variable and often subtle external manifestations of CS, many individuals remain undiagnosed. 56 Both the presence of a germline mutation (in 85% of patients who fulfil the diagnostic criteria of CS a mutation is identified) and the location of the mutation are associated with severity of disease. Because of the risk to develop (multiple) malignant (extra-CNS) tumors survival is limited.
Turcot Syndrome
Turcot syndrome is characterized by the co-occurrence of a primary brain tumor and (multiple) colorectal adenoma(s) or carcinoma. 57 This association was described as possible result from two germline defects: mismatch-repair gene mutations or APC mutations. The pathology of the CNS tumor may help distinguish between the underlying genetic cause. Medulloblastoma are generally associated with APC mutations, whereas glioblastoma are usually associated with mismatch repair gene mutations. 58 It is important to note that in the original consanguineous family described by Turcot et al, 57 one child developed at 15 years multiple polyps with two adenocarcinoma and a spinal medulloblastoma and his sister had multiple polyps at 13 years and developed a glioblastoma at the of age 21 years. We think that this family suffered from constitutional mismatch repair-deficiency syndrome (CCMR-D) and
that the term Turcot syndrome should be revised. Thus far, however, the term Turcot syndrome is being used for the cooccurrence of a primary brain tumor and (multiple) colorectal adenoma(s) or carcinoma. Of note, the association of brain tumors and colon cancer also may occur in LFS, but in this context the term Turcot syndrome is generally not used.
Lynch syndrome
Lynch syndrome (LS; previously known as hereditary nonpolyposis colorectal cancer) predisposes to colorectal cancer and other tumor types (as endometrial, gastric, ovarian, urinary tract, small bowel, pancreas, breast, and sebaceous skin neoplasias). Also brain tumors are associated with LS. 58, 59 Glioma, predominantly glioblastoma, but also ependymoma, high grade astrocytoma and oligodendroglioma, and incidental cases of ganglioma, meningioma, and hemangioblastoma are described in LS. 60, 61 LS is quite common (3-5% of colorectal cancer cases are caused by LS), but a CNS tumor as primary manifestation, especially in children, has not been reported. 61 In adolescents with LS glioblastoma are sporadically described, this may be due to an unidentified constitutional mismatch repair-deficiency syndrome (CMMR-D).
Constitutional Mismatch Repair-Deficiency Syndrome
CMMR-D is caused by mutations of both alleles of one of the four mismatch repair genes. This causes a more severe phenotype with tumors at young age. Children resemble the NF1 phenotype with café-au-lait spots. A minority also have freckling, Lisch nodule, or neurofibroma, although generally no other NF1 features have been seen. 62 Children develop various tumors, predominantly hematological malignancies, brain tumors, and colorectal carcinoma around the age of 10 years. Other LS-associated and not LS-associated tumors are reported in CMMR-D (reviewed in Wimmer and Etzler 62 ). The risk to develop a second malignancy is high. 62, 63 Brain tumors observed at a mean age of 8 years are glioma, predominantly glioblastoma, medulloblastoma, and supratentorial PNET. 62 Pedigree analysis and sometimes parental consanguinity may point to autosomal recessive inheritance; however, with low penetrant mutations negative family histories for LS are common. 64 
Familial Adenomatous Polyposis
Familial adenomatous polyposis (FAP) patients generally have a colorectum carpeted by hundreds to thousands of polyps, which without treatment will lead to colorectal carcinomas. Polyps are usually first detected in adolescence. However, in rare cases the first manifestation of FAP is a medulloblastoma in childhood. Children presenting with medulloblastomas having no evidence of polyps is of poor prognosis. 65 Extracolonic (non)neoplastic manifestations as osteoma, hepatoblastomas, ampulla of vater carcinomas, desmoid tumors, and epidermoid cysts are also associated with APC germline mutations 66 and are known as Gardner syndrome. 67 Efforts are being made to further delineate the observed genotype-phenotype correlation thus far. Several cases of craniopharyngioma in the cerebellopontine angle 68 and also meningioma 69, 70 were reported in Gardner syndrome. Gliomas have been incidentally reported as well, however, this may be erroneous because of confusion in Turcot syndrome. The life-expectancy in FAP patients has significantly increased in the past decennia because of preventive surgical options and ameliorated screening.
Discussion
In 5 to10% of children with cancer an underlying genetic syndrome has been suggested. 12, 71, 72 The development of new molecular techniques and more stringent diagnostic efforts may well cause a further increase of this percentage. This article demonstrates that also in children with brain tumors a significant number of syndromes can be diagnosed, with wide-spread consequences. Merks et al and Méhes 12, 73 have recommended that all children diagnosed with a tumor should be assessed by a clinical geneticist or a pediatrician skilled in clinical morphology.
In some cases, the tumor type itself pinpoints to an underlying syndrome. An example is a child with a CPC, who has a high likelihood to have a germline mutation in TP53 causing LFS even in the absence of a family history suggestive of LFS. Another example is formed by dysplastic gangliocytoma of cerebellum (LDD) which is a pathognomic CNS manifestation of CS. In other cases, various morphological abnormalities may pinpoint to recognizable syndromes. 11, 12, 14 Several CNS tumor predisposition syndromes (such as GS, NF1, NF2, TSC, and VHL) have dermatological manifestations, which can be expected due to their joint embryological origin and are referred to as neurocutaneous syndromes or phakomatoses. 71 Consultation of a dermatologist may be helpful in diagnosing such entities. Absence of skin anomalies does not exclude every phakomatosis completely however, and further studies may still be indicated. The same holds for various other anomalies in tumor predisposing syndromes: it is uncommon that a manifestation is an absolute prerequisite for an entity, and absence does not exclude the entity with certainty. Referral to a clinical geneticist, who is also specialized in obtaining detailed family histories and combines seemingly unrelated data from patients and family members, needs to be considered. 71 An example is the combination of medulloblastoma in a child and young age onset breast cancer and sarcoma in family members, which fulfils LFS criteria.
Once a clinical diagnosis is made or suspected, DNA diagnostics is generally subsequently performed to confirm this. Interpretation of molecular results, particularly of unclassified variants which may be identified in DNA diagnostics, can be difficult. The absence of a likely pathogenic variant in a gene which fits very well the clinical phenotype should not immediately lead to the rejection of the gene as the cause and asks for further analyses. We have also learned that we cannot always rely on investigating DNA derived from lymphocytes in the blood: sometimes a mutation is detectable only in other (tumor) tissues (mosaicism). Well-known examples are Proteus syndrome 74 and Cornelia de Lange syndrome, 75 but it has also been described in segmental NF1 76 and NF2. 77 Evaluation of results of recently developed techniques such as next-generation sequencing, especially wholeexome sequencing, asks for a careful interplay between molecular geneticist, bioinformatician and clinician. Wholeexome sequencing is used in diagnostics for well-known entities for which the causative gene was not identified. 51, 78, 79 Whole-exome sequencing may also be considered in families with a phenotype in which regular clinical and molecular diagnostics have failed to find the cause. A commonly used strategy is checking genes acting in the same pathway(s) as the genes known to cause such phenotypes. An example can be a patient with a phenotype that resembles CS but who has no detectable PTEN mutation. Whole-exome sequencing in such patients has learned that germline mutations in PIK3CA and AKT1, both belonging to the PTEN/PI3K/ AKT pathway can be found. 74 Undoubtedly, further genes acting in this pathway will be found in other, clinically similar patients. The present molecular techniques allow for much more rapid detection of causative genes in rare entities and indeed the number of genes known to cause syndromes is growing enormously. It has led to the understanding that deletions of tumor suppressor genes can cause tumor predisposition phenotypes in the same way as mutations in these genes can do. We also understand now that clinically different entities can be caused by mutations in the same gene. For example, both Turcot and Gardner syndromes can be seen as tails of the FAP spectrum caused by APC mutations. In addition, mutations in SMARCB1 are not only known to be responsible for RTPS and schwannomatosis, but also play a role in other diseases including Coffin-Siris syndrome (CSS). 44 In CSS no increased risk of schwannomas or MRTs has been noticed; however, a medulloblastoma in a child with CSS that was not molecularly confirmed has been described (►Table 1). 80 Diagnosing tumor predisposition syndromes in children has several important consequences. 71 First, syndrome-associated malignancies may have a different prognosis and require specific treatments. Elevated risks for developing secondary malignancies after treatment of the primary tumor may influence the choice of chemotherapy or radiation. Optic nerve gliomas may serve as an example. If treatment is required, optic nerve gliomas are generally treated with radiotherapy, but in the context of NF1, radiotherapy, should be avoided. 81 In several other tumor predisposition syndromes (NF2, LFS, and GS) irradiation should be avoided as well, especially in childhood, as this may induce, accelerate, or transform tumors in children with an inactive tumor suppressor gene. Furthermore, increased intrinsic radiosensitivity and chemosensitivity to standard treatment can be seen in syndromes as Nijmegen breakage syndrome and ataxia telangiectasia (►Table 1), in which DNA repair genes are nonfunctional. In such entities, standard treatments need to be adjusted, otherwise severe unexpected, potentially fatal, toxicity may be observed. 82 Second, some tumor predisposition syndromes require screening for subsequent malignancies. The mere knowledge of the presence of any of the tumor predisposition syndromes listed in ►Table 2 in a child will elicit increased vigilance to warning signs that may reflect an underlying malignancy. If radioimaging is indicated as part of surveillance, MRI imaging is recommended instead of computed tomographic scanning due to the risk for radiationinduced malignancies in most tumor predisposition syndromes. Third, the other, nontumor manifestations of the syndrome may require surveillance or even preventive measurements as well. As example, NF1 individuals should be regularly checked for the development of hypertension due to a higher risk of vascular abnormalities. Finally, tumor predisposition syndromes are hereditary disorders, and siblings, parents, and other family members may be affected as well. Most tumor predisposition syndromes follow an autosomal dominant pattern of inheritance and have recurrence risks of 50% for offspring of an affected individual. If the germline mutation is not de novo, there is a recurrence risk of 50% for all other first degree family members. These family members should be informed about their increased risks to develop cancer, and preventive (screening) options. Prenatal diagnostics and preimplantation diagnostics are options to consider in order not to pass the tumor predisposition syndrome on to offspring. Genetic testing can bring along ethical issues, 83 insecurities on prognosis and quality of life, and patients and their relatives may be hesitant to get tested. Genetic counselling may help them to make the right choices for them in these ethical dilemmas.
A large amount of tumors has been sequenced in the search for therapeutic targets 84 and more studies will probably follow. In those studies, many somatic "driver" mutations are described; however, germline mutations are hardly reported and not generally checked for in research basis. 85 Our ameliorated knowledge of the etiology of cancer is increasingly translated into management strategies in tumor predisposition syndromes. 53 Textbooks (such as Management of Genetic Syndromes by Cassidy and Allanson) 86 and sites (such as Orphanet, http://www.orpha.net/consor/cgi-bin/home. php) are available that describe the general care for individuals with one of the various syndromes described above. Small molecule inhibitors, that act against a particular function of a protein causing tumors, have been developed and are being tested, also in tumor predisposition syndromes. 87 For example, a range of small molecule inhibitors are tested in clinical trials to inhibit growth of neurofibroma and vestibular schwannoma in individuals with NF1 88 and NF2, respectively. 89 In TSC, loss of function mutations in TSC1/TSC2, encoding for the proteins hamartin and tuberin, disrupt the complex of these two proteins and activate mTOR signaling. Indeed, mTOR inhibitors have shown to induce partial regression of SEGA in TSC. 90 It is conceivable that in the near future, such strategies are not only based on this knowledge but also on the specific mutation(s) found in an individual, and that personalized therapy will become possible for tumor predisposition syndromes, also in children (►Table 4).
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